Research programme: anticancer antibodies - BioInvent International/Cancer Research Technology

Drug Profile

Research programme: anticancer antibodies - BioInvent International/Cancer Research Technology

Latest Information Update: 18 Dec 2015

Price : $50

At a glance

  • Originator BioInvent International; Cancer Research Technology; University of Southampton
  • Class Antibodies
  • Mechanism of Action CD137 antigen agonists; Immunostimulants; Macrophage inhibitors; OX40 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Dec 2015 BioInvent in-licenses technology to make efficacious immune stimulatory antibodies from the University of Southampton
  • 21 Apr 2015 BioInvent and Cancer Research Technology entered into collaboration with University of Southampton to co-develop antibodies for Cancer
  • 01 Apr 2015 Pharmacodynamics data from a preclinical trial in Cancer released by BioInvent
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top